Three-Pronged attack on breast cancer shows promise before surgery

NCT ID NCT02520063

Summary

This early-stage study tested a combination of three drugs given to postmenopausal women before breast cancer surgery. The goal was to see if the drugs—two approved and one experimental—could safely shrink tumors by attacking the cancer in different ways. Researchers enrolled 15 women with hormone-positive, HER2-negative breast cancer to find the best dose and get a first look at how well the treatment worked.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

Conditions

Explore the condition pages connected to this study.